Takeda hosts IBD Nexus Summit marking a decade of transformative care for gastrointestinal disease patients

Cairo 03 June 2025:

Takeda, a global biopharmaceutical leader focused on patient care and one of the key players in the Inflammatory Bowel Disease (IBD) space, hosted the IBD Nexus Summit earlier this year, to raise awareness and enhance knowledge about the disease. The summit brought together renowned healthcare professionals and leading experts in the IBD field to focus on developing innovative treatment strategies as part of patient-centered care.

The experts shared their diverse insights into the challenges, opportunities, and advances in IBD care through a series of keynote presentations, panel discussions, and expert-led sessions. Attendees had the opportunity to enhance their understanding of crucial issues such as early diagnosis, personalized treatment options, and the latest breakthroughs in IBD treatment, gaining insights into the ongoing challenges faced by patients, and empowering them to address the existing gaps in IBD care management.

“The ongoing focus of tailoring therapies to meet each patient’s individual needs is driving significant advancements in IBD care. The IBD Nexus Summit, facilitated a collaborative learning environment, enabling healthcare professionals to share expertise on patient awareness and support, which will help enhance IBD management and assist patients in effectively managing their condition.” added, Dr. Ezzat Ali, – President of The Egyptian Society of IBD (ESIBD) and The Egyptian Society of Gastroenterology and IBD (ESGID).

Speaking on the success of the event, Samy Khalil, General Manager for Takeda Egypt, said, “The IBD Nexus Summit stands as a testament to our relentless pursuit of excellence in patient-centered care. By merging cutting-edge research with collaborative dialogue and experience sharing, we are not just advancing treatments—we are reinvigorating hope and redefining the future of IBD care. Every conversation here is a step toward to innovative therapies that empower patients to live a healthier life.”

Takeda is committed to transforming the lives of IBD patients by pioneering innovative treatments and advancing the standard of care. As a leader in advancing scientific research in the field of gastroenterology, Takeda continues to push the boundaries of medical science to offer patients afflicted with IBD the best possible care.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.